Home » CanSino Plans Phase 3 COVID-19 Vaccine Trial in Saudi Arabia
CanSino Plans Phase 3 COVID-19 Vaccine Trial in Saudi Arabia
CanSino Biologics is preparing a phase 3 trial of its COVID-19 vaccine in Saudi Arabia, the country’s Ministry of Health announced.
The study will include at least 5,000 healthy participants over age 18, who will be given either a low dose of the vaccine or the vaccine without any active ingredients.
CanSino’s vaccine has shown efficacy in early phase trials, generating antibodies and good immune responses in the volunteers.
Upcoming Events
-
07May
-
14May
-
30May